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Abstract: In the last several years, we have made slow but steady
progress in developing new treatment strategies for patients with
lung cancer. The use of molecularly targeted therapy has made a
significant impact on the outcomes of patients with lung cancer.
Further research is ongoing to identify more effective ways to target
lung cancer. In the recently concluded 47th annual meeting of the
American Society of Clinical Oncology, there were several presen-
tations on novel targeted therapies for lung cancer, in addition to the
effective and optimal use of existing cytotoxic and targeted therapies
for lung cancer. For this review, we have selected presentations that
primarily have an impact on clinical practice, and some presenta-
tions regarding emerging therapeutic agents.
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The advent of molecularly targeted therapy represents amajor advance in the treatment of lung cancer, with some
remarkable success stories, including the development of
tyrosine kinase (TK) inhibitors that successfully target the
epidermal growth factor receptor (EGFR) and anaplastic
lymphoma kinase (ALK) inhibitors.1,2 However, we are still
far from realizing truly personalized therapy for patients with
lung cancer. Targeted drugs have a meaningful therapeutic
impact only in a small proportion of patients with lung
cancer. For most of patients with advanced lung cancer, there
are no well-established or effective targets and still rely on
cytotoxic chemotherapy treatments. Furthermore, tumors that
are initially sensitive to targeted therapy eventually develop
resistance. There is a need for identifying new molecular
targets for lung cancer, developing effective inhibitors for
known and validated targets, such as K-RAS, and identifying
methods to surmount the eventual development of resistance.
Nevertheless, progress has been slow with only a handful of
targeted therapies showing significant treatment benefit
against lung cancer.
In the recently concluded 47th annual meeting of the
American Society of Clinical Oncology (ASCO), there were
several presentations on novel targeted therapies for lung
cancer, in addition to the effective and optimal use of existing
cytotoxic and targeted therapies for lung cancer. For this
review, we have selected presentations that primarily have an
impact on clinical practice, and some presentations on prom-
ising new findings regarding emerging therapeutic agents.
Metastatic Non-small Cell Lung Cancer
Personalized Therapy for Advanced Non-small
Cell Lung Cancer
The Lung Cancer Mutation Consortium (LCMC) was
established with the goal of developing personalized therapy
for patients with advanced adenocarcinoma of the lung by
studying tumor tissues.3 The consortium consisted of 14
academic institutions and enrolled more than 1000 patients
whose tumor specimens were tested for panel of molecular
alterations, including mutations in the KRAS, EGFR, HER2,
PIK3CA, AKT1, NRAS, MEK1 genes, and EML4-ALK
fusion gene as well as MET amplification. Patients with
activating EGFR-TK mutations were treated with erlotinib
and patients with other driver mutations were offered partic-
ipation in a clinical trial with an agent specific to the target,
when possible.
Of the over 1000 patients enrolled in the consortium,
516 patients underwent testing of the entire panel of 10
different molecular alterations. Two hundred eight patients
(54%) tested positive for a specific molecular alteration.
Approximately 97% of these molecular alterations were mu-
tually exclusive, with the most common ones being mutations
in KRAS (22%) followed by mutations in EGFR-TK (17%)
and EML4-ALK fusion gene (7%). More importantly, muta-
tion detection often influenced treatment decisions; for in-
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stance at one of the sites, 121 patients were enrolled in the
LCMC study, 54% tested positive for a mutation, and 30% of
these patients received therapy targeted to their specific
mutation, with 19 patients receiving erlotinib as initial ther-
apy, and 16 patients being enrolled in one of the eight
industry-sponsored trial linked to this consortium. The future
of lung cancer management will be focused on selecting
targeted therapies based on molecular testing, and LCMC is
an important step in that direction.
First-Line Therapy
The paradigm of administering cytotoxic chemotherapy
to all eligible patients with advanced non-small cell lung
cancer (NSCLC) is slowly changing, with the use of bio-
marker testing to select patients for molecularly targeted
treatment. Prospective randomized trials have established the
effectiveness of gefitinib in the frontline treatment of patients
who test positive for the EGFR-TK mutation.1,4 Nevertheless,
these trials were primarily conducted in Asian populations.
The European Tarceva versus chemotherapy (EURTAC) is a
phase III study comparing single-agent erlotinib to platinum
doublet in the frontline treatment of patients with NSCLC and
had activating EGFR-TK mutations.5 Treatment with erlo-
tinib was associated with a significant improvement in the
primary end point progression-free survival (PFS) in patients
receiving erlotinib compared with patients receiving chemo-
therapy alone; median PFS 9.4 months versus 5.2 months
(hazard ratio [HR], 0.42; p  0.0001). Preliminary data
regarding overall survival (OS) did not identify a significant
difference between the two groups possibly because of cross-
over to erlotinib in the second-line setting; HR  0.8 (95%
confidence interval [CI], 0.47–1.37; p 0.42). Similar results
were reported from the phase III OPTIMAL study, which
randomized patients with EGFR-TK mutations to either er-
lotinib or platinum doublet, with significantly higher PFS in
patients receiving erlotinib, compared with the chemotherapy
group.6 (Table 1) Results from these two studies show that
frontline treatment with erlotinib is an appropriate choice for
previously untreated patients with metastatic NSCLC, whose
tumors have activating mutations of the EGFR-TK domain.
Second-Line Chemotherapy
Targeting Met kinase
The C-MET gene is a potential therapeutic target in
NSCLC, and it is reported to be overexpressed in 75% of
all resected lung adenocarcinoma.7 Furthermore, activation of
the Met TK pathway has been shown to have oncogenic
activity.8 In addition, Met amplification has been associated
with development of resistance in patients with EGFR-TK
mutation treated with gefitinib.9
MetMAb is a monovalent antibody that inhibits the
activation of the C-Met TK receptor by its ligand hepatocyte
growth factor.10 In a phase II randomized trial, patients (n 
137) with advanced NSCLC were randomized to receive
either erlotinib alone or erlotinib with MetMAb in the sec-
ond- and third-line setting with the primary objectives of
determining PFS in the intention-to-treat population and in
patients who were positive for tumor Met expression by
immunohistochemistry (IHC). Patients on the erlotinib only
arm were allowed to crossover to MetMAb on progression.
There was no significant improvement in PFS between the
two study arms in the intention-to-treat population. However,
in patients whose tumor tissue was positive for Met expres-
sion by IHC, there was significant improvement in PFS for
patients treated with MetMAb and erlotinib than patients
receiving erlotinib alone; median PFS 2.9 months versus 1.5
months (p  0.042). Similarly in the Met-positive subgroup,
treatment with MetMAb and erlotinib was associated with
better OS compared with erlotinib alone; median OS 12.6
versus 3.8 months (p  0.002). The addition of MetMAb did
not result in any unexpected toxicities. The findings in this
study suggest that Met expression by IHC can help select
patients who are likely to benefit from the addition of Met-
MAb to erlotinib in the second- and third-line treatment of
advanced NSCLC. The combination of erlotinib and Met-
MAb is now being evaluated in an ongoing phase III trial.
ALK Inhibition in Patients with NSCLC
EML4-ALK is a novel fusion gene present in 5% of
patients with NSCLC and is associated with excellent thera-
peutic response to treatment with an ALK kinase inhibi-
tor.2,11,12 Shaw et al.13 demonstrated that patients with EML4-
ALK fusion protein had a better outcome with crizotinib, a
dual Met and ALK kinase, compared with standard chemo-
therapy, based on a retrospective study, using three different
patient cohorts in the second-line setting—ALK-positive pa-
tients treated with crizotinib (n  30), ALK-positive patients
who did not receive second-line crizotinib (n  23), and
ALK-negative patients (n  125).
Heat shock proteins (Hsp) function as intracellular
chaperones for other proteins to ensure normal cellular func-
tion and also play a role in cancer by promoting the activities
TABLE 1. Phase III Trials of Frontline EGFR-TK Inhibitors in the Treatment of Advanced NSCLC
References





Response Rate (%) Median PFS (Months) Median OS (Months)
Chemotherapy EGFR-TKI Chemotherapy EGFR-TKI Chemotherapy EGFR-TKI
EURTAC5 174 Erlotinib 11 55 5.2 9.4 — —
OPTIMAL6 165 Erlotinib 36 83 4.6 13.7 — —
IPASS1 261 Gefitinib 47 71 6.3 9.5 21.9 21.6
NEJ 0024 200 Gefitinib 31 74 5.4 10.8 23.6 30.5
WJTOG 340532 177 Gefitinib 32 62 6.3 9.2 — —
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival.
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of other oncogenic proteins.14 In an open label phase II study,
96 patients with relapsed/refractory NSCLC were treated
with Hsp90 inhibitor STA-9090.15 The study included mo-
lecular analysis of tumor tissue to detect EGFR, KRAS, and
BRAF mutation status; in addition, fluorescent in situ hybrid-
ization and polymerase chain reaction testing for EML4-ALK
fusion gene were also performed. Of the four responders in
this study, all of them tested positive for the EML4-ALK
fusion gene by either polymerase chain reaction or fluores-
cent in situ hybridization. The treatment was overall well
tolerated, and the common adverse events were grade 2
diarrhea, nausea, and fatigue. These interesting results require
further evaluation and independent confirmation. If con-
firmed, Hsp90 inhibition may present a novel therapeutic
option to target the EML4-ALK fusion gene.
Maintenance Therapy
Maintenance therapy after induction with frontline plat-
inum doublet chemotherapy has now become an important
tool in the armamentarium of the oncologist treating patients
with advanced NSCLC (Table 2). Previous phase III trials
have primarily focused on “switch maintenance” therapy, in
which a different drug is used for maintenance treatment,
after completing platinum doublet induction therapy.16–19
The PARAMOUNT study is the first phase III randomized
trial to explore the benefit of “continuation maintenance,” in
which the drug used in the maintenance phase is part of the
initial induction therapy. In this trial, treatment naive patients
with advanced NSCLC, with stable disease or partial re-
sponse after four cycles of platinum and pemetrexed combi-
nation, were randomized to receive either maintenance pem-
etrexed or placebo, with the primary end point of PFS.20
Patients receiving pemetrexed maintenance had better (inde-
pendently assessed) PFS than patients receiving placebo; 3.9
months versus 2.6 months; p  0.0002. Maintenance of
pemetrexed was associated with higher incidence of fatigue
and cytopenias, but there were no unexpected toxicities.
“Switch maintenance” with erlotinib in unselected pa-
tients has been shown to prolong PFS compared with placebo
alone after induction with platinum-based chemotherapy.17–19
The INFORM was a randomized trial in which patients from
China (n  296) with advanced NSCLC were randomized to
receive gefitinib or placebo if they had stable disease or
response after four cycles of platinum doublet chemother-
apy.21 The primary end point was PFS, and gefitinib mainte-
nance was associated with improved PFS compared with
placebo; 4.8 months versus 2.6 months; p  0.0001. Tumor
tissue was available for EGFR-TK mutations testing in a
small number of patients (n 79). Subanalysis identified that
patients (n  30) with activating mutations in the EGFR-TK
domain had better PFS with gefitinib maintenance than pla-
cebo; 16.6 months versus 2.8 months. There was no signifi-
cant improvement in PFS with gefitinib maintenance for
patients with the wild-type EGFR-TK gene. In the phase III
SATURN trial, maintenance therapy with erlotinib was asso-
ciated with improved PFS in patients with EGFR-TK muta-
tions (HR  0.1; 95% CI, 0.04–0.25; p  0.0001) and
patients with wild-type EGFR (HR  0.78; 95% CI, 0.63–
0.96; p  0.02). However, the magnitude of benefit was
significantly better in patients with activating EGFR-TK
mutations.22 Results from these two studies suggest that
benefit from maintenance therapy with EGFR-TK inhibitors
is primarily in patients with activating EGFR mutations.
Preliminary findings from the INFORM and
PARAMOUNT studies have shown small but significant im-
provement in PFS from maintenance therapy with either pem-
etrexed or an EGFR-TK inhibitor. Subset analysis from the
INFORM trial indicates that the benefit from gefitinib mainte-
nance may be confined to patients with EGFR-TK mutations.
The PARAMOUNT study shows that continuation mainte-
nance with pemetrexed is effective and safe. Taken together
with previous phase III studies (Table 2), it is clear that
maintenance therapy improves PFS in patients with NSCLC










Paz-Ares et al.20 939 Cisplatin  pemetrexed 539 Pemetrexed 3.9 0.0002
Placebo 2.6
Zhang et al.21 — Platinum doublet 296 Gefitinib 4.8 0.0001
Placebo 2.6
Ciuleanu T et al.33 — Platinum doublet 663 Pemetrexed 4.3 0.0001
Placebo 2.6
Fidias et al.16 566 Carboplatin  Gemcitabine 309 Docetaxel 5.7 0.0001
Placebo 2.7
Perol et al.19 834 Cisplatin  gemcitabine 309 Gemcitabine 3.8 0.002
Placebo 1.9
Perol et al.19 834 Cisplatin  gemcitabine 309 Erlotinib 2.9 0.002
Placebo 1.9
Cappuzzo et al.17 1949 Platinum doublet 889 Erlotinib 2.9 0.0001
placebo 2.6
Kabbinavar et al.18 — Platinum doublet  bevacizumab 768 Erlotinib  bevacizumab 4.8 0.012
Bevacizumab 3.8
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who benefit from frontline platinum-based therapy. However,
improvement in PFS did not result in better quality of life,
and most maintenance studies did not show an improvement
in OS.23 There are also issues with the study design of these
trials because a third of the patients in the placebo or obser-
vation arm did not receive second-line therapy, and there was
significant treatment variation in patients who did receive
second-line therapy. It is important that these issues are
addressed in future maintenance studies in NSCLC.
Resectable NSCLC
Adjuvant Chemotherapy in Patients with Stage IB
Disease
The benefit of adjuvant chemotherapy is clear in pa-
tients with stage II and III disease, but remains unclear in
patients with stage IB disease. The Cancer and Leukemia
Group B 9633 study failed to demonstrate a survival advan-
tage for adjuvant chemotherapy in the intention-to-treat pop-
ulation, although an unplanned subset analysis had suggested
a statistically significant improvement in survival in patients
with tumors 4 cm, who were treated with chemotherapy.24
An updated report of the Cancer and Leukemia Group B 9633
study was presented at this year’s ASCO annual meeting.25
After a 9-year median follow-up, there continues to be a lack
of demonstrable survival benefit of adjuvant chemotherapy in
these patients, and the questionable survival benefit in pa-
tients with tumors 4 cm was also lost according to the
updated analysis, although a trend toward improved survival
in patients treated with chemotherapy continued to be ob-
served (HR, 0.78; p  0.087). Patients were also stratified
according to the new tumor (T) stage descriptors. Again,
there was a trend toward improved survival in patients with
tumors over 5 cm with a statistically significant improvement
in survival in patients with tumors over 7 cm in size, who
were treated with adjuvant chemotherapy (HR, 0.52; p 
0.048). These results should be interpreted with caution,
because this study was underpowered to detect its primary
end point as a result of poor accrual, and these exploratory
subgroup analyses were not preplanned. Of note, the updated
survival analysis of the JBR.10 adjuvant chemotherapy trial,
which included patients with stage I and II disease, did not
demonstrate a significant improvement in survival in patients
with stage IB disease, irrespective of tumor size cutoffs.26
The role of adjuvant chemotherapy in stage IB in general
remains unclear, although there may be patient subsets that
benefit from it.
Improving Dose Delivery and Tolerability of
Adjuvant Chemotherapy
Toxicity of adjuvant cisplatin-based chemotherapy is
an issue we often have to contend with, and this often results
in incomplete treatment, treatment refusal, treatment delays,
and dose reductions. The most widely studied regimen in the
adjuvant setting is the combination of cisplatin and vinorel-
bine. Pemetrexed along with cisplatin has been demonstrated
to improve survival in patients with metastatic disease, al-
though this benefit was primarily seen in patients with nons-
quamous histology. Extrapolating from the data in the meta-
static setting, in practice, cisplatin and pemetrexed is being
used in the adjuvant setting and is endorsed by the National
Comprehensive Cancer Network as an alternative treatment
regimen. This combination was studied in a randomized
phase II trial, comparing cisplatin and pemetrexed with cis-
platin and vinorelbine in the adjuvant setting, with the pri-
mary end point of feasibility, which was defined as no death
from cancer, toxicity or comorbidity, no premature withdraw-
als, and no dose-limiting toxicity.27 Secondary end points
were drug delivery and efficacy. Of the 132 patients random-
ized, 43% had squamous histology and 38% had stage IB
disease. The study met its primary end point with a feasibility
rate of 95.5% for cisplatin and pemetrexed (95% CI, 87.5–
99.1), compared with a rate of 75.4% (95% CI, 63.1–85.2)
for cisplatin and vinorelbine; p 0.001. The lower feasibility
rate with cisplatin and vinorelbine was primarily due to a
higher rate of dose-limiting toxicity (15.4 compared with 3%)
and withdrawal of consent (6.2 versus 0%). Drug delivery
was also superior for the cisplatin and pemetrexed arm. For
efficacy data, a longer follow-up is needed, although how we
would interpret these data is unclear, given the high rate of
patients with squamous histology and stage I disease.
Adjuvant Chemotherapy in the Elderly
Subgroup analysis of the JBR.10 and LACE meta-
analysis demonstrated a benefit of adjuvant cisplatin-based
chemotherapy in elderly patients with NSCLC, with accept-
able toxicity. However, the actual utilization of adjuvant
chemotherapy in the elderly population (older than 70 years)
with NSCLC is not known. Cuffe et al.28 described the use of
chemotherapy in elderly patients with NSCLC, using the
population-based Ontario Cancer Registry, and identified
6304 patients between 2001 and 2006, who underwent resec-
tion for NSCLC, of which 2746 were elderly (older than 70
years). Use of adjuvant chemotherapy was noted to decline
by age, with 43% of patients younger than 70 years, 23% in
70 to 74 years, 13% in 75 to 79 years, and 5% older than 80
years receiving adjuvant platinum-based chemotherapy. Ap-
proximately 70% of elderly patients who received adjuvant
chemotherapy were treated with cisplatin, compared with
85% of those younger than 70 years. Dose modifications and
substitutions were similar in patients younger than 70 years.
Although the use of adjuvant chemotherapy was seen to
decline by age, in this study adjuvant chemotherapy was
associated with a statistically significant survival benefit in
elderly patients.
Cisplatin Versus Carboplatin in the Adjuvant
Setting
Gu et al.29 retrospectively compared the outcome of
patients with NSCLC who received cisplatin and carboplatin-
based chemotherapy using the Surveillance Epidemiology
End Results Medicare database. This study included 3324
patients above 65 years, who underwent resection for stage II
to IIIA NSCLC between 1992 and 2005. Of these patients,
19% received platinum-based adjuvant chemotherapy within
3 months of surgery, with better survival outcome compared
with patients who did not receive adjuvant chemotherapy
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(HR, 0.79; 95% CI, 0.71–0.89). Carboplatin was the more
commonly used regimen (76.9%) and no survival difference
was observed between the groups who received cisplatin or
carboplatin. Although these findings are intriguing, there are
no prospective studies to support the use of carboplatin-based
adjuvant chemotherapy.
Small Cell Lung Cancer
Amrubicin is a third-generation synthetic anthracycline
derivative that showed a significant improvement in response
rates compared with topotecan (44 versus 15%, p  0.02) in
patients with chemotherapy-sensitive SCLC.30 Although nei-
ther the PFS (4.5 versus 3.3 months) nor the OS (9.2 versus
7.6 months) reached statistical significance, the encouraging
results from the phase II trial led to the ACT-1, a large
randomized phase III trial where 637 patients with either
sensitive or refractory disease were randomized in a 2:1 ratio
to receive amrubicin 40 mg/m2 on days 1 to 3 or topotecan
1.5 mg/m2 from days 1 to 5, with OS as the primary end
point.31 Similar to the results from the phase II study, amru-
bicin was associated with a significant improvement in re-
sponse rates (31 versus 17%, p  0.0002) but not in OS (7.5
versus 7.8 months). In the subset of patients with refractory
disease, there was a small benefit from amrubicin (6.2 versus
5.7 months, p  0.047). It is difficult to make meaningful
progress in the treatment of SCLC, without understanding the
biology of this disease, particularly in the case of relapsed
SCLC.
CONCLUSION
The presentations from 47th annual meeting of the
ASCO address several questions relevant to the clinical
management of lung cancer including the role of first-line
treatment with erlotinib, maintenance therapy with pem-
etrexed and gefitinib, and adjuvant chemotherapy in patients
with stage I disease. There were also several presentations on
emerging targeted therapies, and more importantly the
LCMC consortium is an important step toward developing
personalized therapy for patients with NSCLC. However, this
is only a beginning and further efforts are required to develop
effective customized treatments for lung cancer. It is likely
that the ongoing large-scale lung cancer sequencing efforts
will shed considerable light on novel targets and tumor
biology. Future efforts on developing targeted therapies
should focus, first and foremost, on identifying appropriate
molecular subsets.
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